Drugs / Monovalent inactivated influenza vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00841646 | Dec 2008 → Jul 2009 | — | Novartis Vaccines | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00848029 | Nov 2008 → Jun 2009 | — | Novartis Vaccines | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Monovalent inactivated influenza vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00841646 ↗ |
| Modality | Vaccine | “MF59-adjuvanted, prepandemic influenza vaccine” PMID 23081815 ↗ Oct 2012 |